Why Axsome Therapeutics shares are falling today
Investivoq PriceTracker
Axsome Therapeutics (AXSM) is down 5.8% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver appears to be a continuation of recent weakness rather than a fresh company-specific setback. This could be because investors are reacting to a string of recent analyst price-target cuts, a sharp pullback from September highs, and the lack of a new near-term catalyst ahead of the company’s next earnings report on November 2, 2026.
Details:
Sources:
Axsome Therapeutics, SEC, Benzinga, Yahoo Finance
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$AXSM Insider Trading Activity
$AXSM insiders have traded $AXSM stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:
- HERRIOT TABUTEAU (Chief Executive Officer) has made 0 purchases and 4 sales selling 149,000 shares for an estimated $34,441,528.
- NICK PIZZIE (Chief Financial Officer) sold 33,000 shares for an estimated $7,922,970
- MARK COLEMAN has made 0 purchases and 4 sales selling 18,180 shares for an estimated $4,179,577.
- MARK L. JACOBSON (Chief Operating Officer) has made 0 purchases and 3 sales selling 14,750 shares for an estimated $3,169,270.
- ARI MAIZEL (Chief Commercial Officer) sold 7,500 shares for an estimated $1,368,150
- SUSAN MAHONY has made 0 purchases and 2 sales selling 600 shares for an estimated $145,017.
- ROGER JEFFS has made 0 purchases and 2 sales selling 572 shares for an estimated $141,655.
To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.
$AXSM Hedge Fund Activity
We have seen 282 institutional investors add shares of $AXSM stock to their portfolio, and 186 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 809,136 shares (-20.7%) from their portfolio in Q2 2026, for an estimated $198,052,218
- PRICE T ROWE ASSOCIATES INC /MD/ removed 674,166 shares (-51.2%) from their portfolio in Q2 2026, for an estimated $165,015,611
- MILLENNIUM MANAGEMENT LLC added 535,330 shares (+2578.9%) to their portfolio in Q2 2026, for an estimated $131,032,724
- WELLINGTON MANAGEMENT GROUP LLP removed 491,386 shares (-42.9%) from their portfolio in Q2 2026, for an estimated $120,276,551
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 478,544 shares (-64.9%) from their portfolio in Q2 2026, for an estimated $117,133,214
- DEEP TRACK CAPITAL, LP removed 400,000 shares (-36.4%) from their portfolio in Q2 2026, for an estimated $97,908,000
- JANE STREET GROUP, LLC added 399,917 shares (+9806.7%) to their portfolio in Q2 2026, for an estimated $97,887,684
To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.
$AXSM Price Targets
Multiple analysts have issued price targets for $AXSM recently. We have seen 10 analysts offer price targets for $AXSM in the last 6 months, with a median target of $271.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $290.0 on 07/08/2026
- Leonid Timashev from RBC Capital set a target price of $304.0 on 07/07/2026
- Joseph Thome from TD Cowen set a target price of $300.0 on 06/17/2026
- Ami Fadia from Needham set a target price of $267.0 on 05/05/2026
- Joel Beatty from Baird set a target price of $246.0 on 05/05/2026
- Benjamin Burnett from Wells Fargo set a target price of $255.0 on 05/05/2026
- Yatin Suneja from Guggenheim set a target price of $260.0 on 05/05/2026
This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.